Authum Investment & Infrastructure Limited has informed the Exchange about Acquisition of Shares of OneSource Specialty Pharma Limited in continuation to the disclosure dated June 13, 2025.
AIIL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Authum Investment & Infrastructure Limited acquired 39.27 lakh shares of OneSource Specialty Pharma Limited (formerly Stelis Biopharma) from Devicam Capital LLP and Pronomz Ventures LLP on June 13, 2025, giving it 3.43% voting rights on a fully diluted basis. The deal was valued at approximately ₹796.4 crore, based on a fair market value of ₹2,028 per share on NSE. OneSource Specialty Pharma is a listed pharmaceutical CDMO (Contract Development and Manufacturing Organization) with a net worth of ₹5,880 crore and FY25 turnover of ₹1,444.8 crore, showing sharp revenue growth from just ₹41 crore in FY23. The acquisition is a commercial transaction with no related-party angle and no regulatory approvals required.
This is a major ₹796+ crore strategic investment by Authum into India's specialty pharma CDMO space, which has shown explosive revenue growth. The 3.43% passive stake is well below the 5% open-offer threshold, so no mandatory offer is triggered. Investors should monitor whether Authum builds a larger position or takes a more active role in OneSource going forward.